Navigation Links
Oncolytics Biotech Inc. Successfully Completes 100-Litre cGMP Production of REOLYSIN(R)
Date:7/27/2009

CALGARY, July 27 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ: ONCY) announced today that with the support of its contract manufacturer, SAFC Pharma(R), a Division of Sigma-Aldrich Corporation, it has successfully completed an initial 100-litre production run of REOLYSIN under cGMP conditions. This run is anticipated to be the first of a series to be completed over the next several years as Oncolytics provides product for its existing clinical trials and continues preparations toward commercial launch of REOLYSIN.

"The manufacturing program is an integral part of the Company's development plan for REOLYSIN," said Dr. Matt Coffey, Chief Operating Officer of Oncolytics. "With the clinical results reported to date and the expected initiation of our pivotal program this year, keeping pace with the manufacturing process is critical."

About Oncolytics Biotech Inc.

Oncolytics is a Calgary-based biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics. Oncolytics' clinical program includes a variety of Phase I/II and Phase II human trials using REOLYSIN, its proprietary formulation of the human reovirus, alone and in combination with radiation or chemotherapy. For further information about Oncolytics, please visit www.oncolyticsbiotech.com

This press release contains forward-looking statements, within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements, including the Company's expectations related to the sufficiency of the 100 litre cGMP manufacturing process, and the Company's belief as to the potential of REOLYSIN as a cancer therapeutic, involve known and unknown risks and uncertainties, which could cause the Company's
'/>"/>

SOURCE Oncolytics Biotech Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. Oncolytics Biotech(R) Inc. Completes Lyophilization Process for REOLYSIN(R)
2. Oncolytics Biotech(R) Inc. Research Collaborators Present Glioma Reovirus Research at ASV Annual Meeting
3. Oncolytics Biotech(R) Inc. Completes Patient Enrolment in U.K. Combination REOLYSIN(R) and Paclitaxel/Carboplatin Head and Neck Cancer Trial
4. Oncolytics Biotech(R) Inc. Collaborators Present Positive Phase II Sarcoma Trial Results at ASCO Annual Meeting
5. Oncolytics Biotech(R) Inc.s Research Collaborators to Present Data on REOLYSIN(R) Clinical Trials at ASCO Conference
6. Oncolytics(R) Biotech Inc. Completes Patient Enrolment in U.S. Phase 2 Sarcoma Study
7. Oncolytics Biotech(R) Inc. Announces 2009 First Quarter Results
8. Oncolytics Biotech(R) Inc. Announces Details of 2009 Annual Shareholder Meeting
9. Media Advisory - Oncolytics Biotech(R) Inc. to Present at BioFinance 2009
10. Oncolytics Biotech(R) Inc. Announces Positive Results of U.K. Phase II REOLYSIN(R) and Radiation Combination Clinical Trial
11. Oncolytics Biotech(R) Inc. Completes Enrolment in Combination REOLYSIN(R)/Gemcitabine Trial

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2009)...c. 2 Reportlinker.com announces th...s catalogue: ,, Carbondioxide Incubators - A G...linker.com/p0164368/Carbondioxide-Incubators---A-G...re the most critical equipment used in microbiolog...ons for providing a controlled environment to grow...
(Date:12/2/2009).... 2 /PRNewswire-FirstCall/ - Oncolytics Biotech In...Q: ONCY ) announced today that in connection with ...riters have exercised in full their over-allotment... Each unit is comprised of one common share and 0.... at a price of US$3.00 per unit. Each whole common...
(Date:12/2/2009)...c. 2 S*BIO Pte Ltd today announced...or, SB1518, at The American Society of Hematology ... ,, Data will be presented on the clinical resu...18 detailing its safety, tolerability and pharmaco...vels ranging from 100 to 600 mg. These doses were ...
(Date:12/2/2009)...cientist, a leading scientific magazine covering t...e “Intelligent” EMCCD camera fourth am...ons of 2009. , (PRWEB) De... from Photometrics ®, a designer and manufac...r the life sciences, was ranked fourth among The S...
Breaking Biology Technology:Reportlinker Adds Carbondioxide Incubators - A Global Market Perspective 2Reportlinker Adds Carbondioxide Incubators - A Global Market Perspective 3Reportlinker Adds Carbondioxide Incubators - A Global Market Perspective 4Oncolytics Biotech(R) Inc. Announces Exercise of Underwriters' Over-Allotment Option 2Oncolytics Biotech(R) Inc. Announces Exercise of Underwriters' Over-Allotment Option 3Oncolytics Biotech(R) Inc. Announces Exercise of Underwriters' Over-Allotment Option 4S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 2S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 3S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 4S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 5The Scientist Names Photometrics' Evolve EMCCD Camera One of the “Top 10 Innovations” of 2009 2The Scientist Names Photometrics' Evolve EMCCD Camera One of the “Top 10 Innovations” of 2009 3
..., Inc.,(Nasdaq: MITI ) ("Micromet" or the "Compan... proprietary antibodies for the treatment of cance...unced the appointment of,Barclay A. Phillips as Se...r. Phillips has served as a member of the Company,... of the nominating & corporate governance,committe...
... 2 /PRNewswire-FirstCall/ - OncoGenex,Pharmaceutic...mpany") has,announced today that it has granted to...de rights to develop and commercialize TOCOSOL(R),...Genex is entitled to,receive royalty payments from...of sub-licensing royalty and milestone payments re...
...ire/ -- Sinovac Biotech Ltd. (Amex:,SVA), a vaccin...y that Mr.,Weidong Yin, Chairman, President and CE...ncial Group,s Second Annual Beijing Management Sum...ijing, China. Sinovac,s,presentation is scheduled ...Sinovac, Sinovac Biotech Ltd. is a China-based bi...
Other Biology Technology:Micromet, Inc. Appoints Barclay Phillips as Senior Vice President and Chief Financial Officer 2Micromet, Inc. Appoints Barclay Phillips as Senior Vice President and Chief Financial Officer 3Micromet, Inc. Appoints Barclay Phillips as Senior Vice President and Chief Financial Officer 4OncoGenex Pharmaceuticals announces out-license of TOCOSOL Paclitaxel to Eagle Pharmaceuticals 2OncoGenex Pharmaceuticals announces out-license of TOCOSOL Paclitaxel to Eagle Pharmaceuticals 3Sinovac to Present at the Susquehanna Financial Group's Second Annual Beijing Management Summit Conference 2
(Date:12/2/2009)...a cap is good for you, at least if you are a mamma...ineering in Oncology Center have shown that in hea...holds the cell,s nucleus, its genetic storehouse, ...uence on cell and nuclear shape, the researchers s...ment of diseases such as cancer, muscular dystroph...
(Date:12/2/2009)...if., Dec. 2 DigitalPersona, Inc., ...n solutions, today announced an agreement with IBM...tric fingerprint technology on IBM SurePOS 500 ret...HD offering allows point-of-sale applications to m...ific transactions can be linked to the individuals...
(Date:12/2/2009)...09 Commonly prescribed beta 2 adrenergic agonist ...n as well as pre-term labor may increase the incid...hology, cognitive problems and poor school perform...ublished in the December 2009 issue of the Americ... adrenergic agonist drugs as a class are widely us...
Breaking Biology News(10 mins):A cell's 'cap' of bundled fibers could yield clues to disease 2DigitalPersona Fingerprint Sensor Technology Ships on IBM SurePOS 500 Retail Systems 2Treatments for asthma and pre-term labor may increase risk of autism in developing fetus 2Healthplace America Names Robert A Yungk Chief Executive Officer 51123 1Healthplace America Names Robert A Yungk Chief Executive Officer 51123 2Healthplace America Names Robert A Yungk Chief Executive Officer 51123 3Compirion Healthcare Sponsors Webinar Series 51121 1Compirion Healthcare Sponsors Webinar Series 51121 2New Tools Help Parents Reinforce Anti Smoking Message 51119 1New Tools Help Parents Reinforce Anti Smoking Message 51119 2
...g provider of non-invasive orthopaedic products an...s Asia Pacific operations in Shanghai, China. Ossu...prosthetics and a comprehensive range of braces an...gional headquarters catering to customers not just...orea and Australia. , The total prosthetic market...
... pathogen may be answered as scientists study the ...awns the worst cereal grains disease known and als...nd livestock. , The fungus, which is especially d... estimated $10 billion in damage to U.S. crops ove...the fungus, genes said that the genome will help t...
...otential for use as cellular probes. As nanopipes ...ells and inject solutions or drugs directly into i...he cells. In addition, because of the small diamet...o cells upon penetration. By making these probes a...hemical interactions within the cells could be fou...
Other Biology News:Ossur -- leading orthopedic pioneer - expands network to Asia 2Ossur -- leading orthopedic pioneer - expands network to Asia 3Fungus genome yielding answers to protect grains, people and animals 2Fungus genome yielding answers to protect grains, people and animals 3
...single cells, or clusters, with rapid, smooth, pre... be targeted, then click-click on the keypad...the...ally transferred to the individual wells of a micr...sion system allows transfer of 1-5 cells at a time...
...A expression profiling and built on the flexible a... platform. These microarrays are available as part...g Service. Probe Content The Maize microRNA Mic...que mature sequences). The comprehensive probe con...
...ance of the LTQ, incorporating more techniques to ...entifics innovations in ion trap technology. Ther...er that offers multiple dissociation techniques, P...ciation (PQD) is a patented technique that elimina...
Varian CP-4900 Micro-GC from Varian, Inc.
Biology Products: